灯盏细辛对急性冠脉综合征患者血浆纤溶活性及C-反应蛋白的影响

Effects of Erigeron Breviscapus on Plasminogen Activator Inhibitor and C-reactive Protein in Acute Coronary Syndrome

将 6 0例急性冠脉综合征 (ACS)患者随机分为灯盏细辛治疗组 30例和对照组 30例 ,2组均按ACS常规治疗 ,治疗组另加用灯盏细辛注射液静滴 ,治疗 4周。观察灯盏细辛对ACS的临床疗效及对ACS患者血浆纤溶酶原激活物 (tPA)及抑制物 (PAI 1 )和C 反应蛋白 (CRP)的影响。结果 :治疗组总有效率为 88.0 % ,明显优于对照组 6 3.7% (P <0 .0 5 ) ;经灯盏细辛治疗后PAI 1及CRP的含量均明显减少 ,与对照组比较差异显著(P <0 .0 5 )。结论 :灯盏细辛治疗急性冠脉综合征疗效肯定 。

Sixty cases of acute coronary syndrome(ACS)were randomly and averagely divided into erigeron breviscapus(EB) treatment group and routine treatment group.The effects of EB on plasminogen activator inhibitor(PAI 1)and C reactive protein(CRP)functions after four weeks treatment in two groups were observed.The results showed that the total effective rate was significantly higher in treatment group(88.0%)than in control group(63.7%),P<0.05.The indexes of PAI 1 and CRP level were lower in treatment group than those in control group(P<0.05).It indicates that EB is an effective drug for ACS,and it obviously improves fibrinolytic activity and relieves inflammatory reaction.\;